ALK and non-small cell lung carcinoma: KEYNOTE-189, compared platinum (carboplatin or cisplatin) plus pemetrexed +/− pembrolizumab in patients with untreated metastatic non-squamous NSCLC without EGFR mutations or ALK rearrangements.